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Abstract: 1 
We have previously characterized mouse cytomegalovirus (MCMV)-encoded immune 2 
evasive interferon (IFN) signalling inhibition and identified the viral protein pM27 as inducer 3 
of proteasomal degradation of STAT2. Extending our analysis to STAT1 and STAT3, we 4 
found that MCMV infection neither destabilizes STAT1 protein nor prevents STAT1 tyrosine 5 
Y701 phosphorylation, nuclear translocation or the capability to bind GAS DNA-enhancer 6 
elements. Unexpectedly, the analysis of STAT3 revealed an induction of STAT3 Y705 7 
phosphorylation by MCMV. In parallel, we found decreasing STAT3 protein amounts upon 8 
MCMV infection although STAT3 expression normally is positive autoregulative. STAT3 9 
phosphorylation depended on the duration of MCMV infection, the infectious dose and 10 
MCMV gene expression but was independent of IFNAR1, IL-10, IL-6 and JAK2. Although 11 
STAT3 phosphorylation did not require MCMV immediate early (IE)1, pM27 and late gene 12 
expression, it was restricted to MCMV-infected cells and not transmitted to bystander cells. 13 
Despite intact STAT1 Y701 phosphorylation, IFNγ-induced target gene transcription (e.g. 14 
IRF1 and SOCS1) was strongly impaired. Likewise, the induction of STAT3 target genes (e.g. 15 
SOCS3) by IL-6 was also abolished, indicating that MCMV antagonizes STAT1 and STAT3 16 
despite the occurrence of tyrosine phosphorylation. Consistent with the lack of SOCS1 17 
induction, STAT1 phosphorylation was prolonged upon IFNγ treatment. We conclude that the 18 
inhibition of canonical STAT1 and STAT3 target gene expression abrogates their intrinsic 19 
negative feedback loops, leading to accumulation of phospho-Y-STAT3 and prolonged 20 
STAT1 phosphorylation. 21 
These findings challenge the generalization of Tyr-phosphorylated STATs necessarily being 22 
transcriptional active and document antagonistic effects of MCMV on STAT1/3-dependent 23 
target gene expression. 24 
(250 words) 25 
26 
 3 
Introduction 1 
Cytomegaloviruses (CMVs) are prototypical β-herpesviruses with an enveloped virion 2 
coating a large double stranded DNA genome of ~230 kbp which encodes numerous viral 3 
proteins. Upon infection, CMVs initiate a sequential and highly coordinated gene expression 4 
profile, starting with immediate early (IE) transcripts, followed by early and late gene 5 
products - the latter being simultaneously expressed with and depending on genome 6 
amplification by rolling circle replication. 7 
Although the infection in healthy individuals is mostly asymptomatic due to virus control by a 8 
concerted response of the innate and adaptive immune system (1), primary as well as 9 
recurrent CMV infections cause symptomatic or even fatal pathologies in immuno-10 
compromised or immature individuals. Irrespective of their robust immune stimulatory 11 
capacity, CMVs circumvent sterile immunity and instead establish a lifelong latency. 12 
Reactivation occurs upon immuno-suppressing and/or stressful conditions due to (re-) 13 
initiation of the lytic viral replication program. Human CMV (HCMV, HHV-5, taxonomy ID: 14 
10359) frequently causes congenital infections via a vertical transmission from the mother to 15 
the developing foetus and constitutes the most frequent non-genetic congenital complication 16 
in western countries (2). 17 
CMVs have undergone an intimate and long lasting co-adaptation with their respective host 18 
species and are thus highly species-specific, which restricts efficient viral replication to cells 19 
of the native host species and thereby excludes experimentation with HCMV in animal 20 
models. The related mouse cytomegalovirus [MCMV, Murid herpesvirus 1, taxonomy ID: 21 
10366]) has a co-linear and partially homologous genome and infects mice (Mus musculus, 22 
taxonomy ID: 10090) allowing to study cytomegaloviral pathogenesis. Additionally, MCMV 23 
represents one of the few DNA viruses naturally infecting Mus musculus as its native host and 24 
has therefore become a widely used model to explore virus-host interactions and to assess 25 
their consequences in vivo. 26 
Among the earliest immune responses raised against viruses is the secretion of interferons 27 
(IFNs). IFNs are pleiotropic cytokines expressed upon encounter of pathogens or their 28 
pathogen-associated molecular patterns (PAMPs). IFNs bind to specific cell surface resident 29 
IFN receptors and subsequently induce a rapid janus kinase (JAK) mediated phosphorylation 30 
of signal transducer and activator of transcription (STAT) which than instruct specific 31 
transcriptional programs to (re-)enforce intrinsic resistance, induce innate immunity and 32 
stimulate and recruit adaptive immune responses. Thereby, IFNs orchestrate the induction of 33 
an antiviral state that efficiently restricts viral replication (3). 34 
 4 
Type I IFNs (IFNα/β) mainly induce STAT1 and STAT2 Tyr (Y) phosphorylation (residues 1 
Y701 and Y689, respectively) upon binding of the IFN to the heterodimeric IFNAR1-2 
IFNAR2 receptor complex and the accompanying activation of the receptor-associated 3 
kinases JAK1 and tyrosine kinase 2 (Tyk2). STAT3 becomes also Y-phosphorylated (at 4 
residue Y705) by type I IFNs. These STAT Y-phosphorylation events are essential for 5 
transcriptional activation of STAT molecules (4-7) and are thus widely considered to 6 
constitute a hallmark and faithful surrogate marker for STAT activation. Phosphorylated 7 
STAT1 and STAT2 recruit IRF9 to form the IFN-stimulated gene factor 3 (ISGF3), which 8 
binds to IFN-stimulated response elements (ISRE) to recruit the transcriptional machinery and 9 
stimulate the expression of adjacent genes. In contrast, IFNγ mainly signals via Y-10 
phosphorylated STAT1 homodimers which are induced upon binding of IFNγ to the 11 
heterodimeric IFNGR1-IFNGR2 receptor and the activation of JAK1 and JAK2. 12 
Besides IFNs, STAT3 Y705 phosphorylation is also induced by a broad variety of growth 13 
factors and cytokines (e.g. IL-6, IL-10, EGF, LIF, OSM and Leptin). It is noteworthy that 14 
STAT3-activating stimuli play an important role in CMV biology. For example, IL-6 15 
transcripts are strongly induced in HCMV-infected cells (8, 9) stimulating IL-6 secretion (10). 16 
Interestingly, recent results document an important regulation of HCMV reactivation by IL-6 17 
(11-13). Additionally, MCMV induces the expression of IL-10 to suppress MHC class II 18 
presentation (14). HCMV encodes a STAT3-activating IL-10 homolog acquired by molecular 19 
piracy (15). 20 
Viruses counteract the antiviral activity of the IFN system by expressing IFN antagonists, 21 
targeting e.g. JAK-STAT signal transduction (16, 17). We have identified and characterized 22 
the MCMV-encoded IFN inhibitor pM27. Replication of a M27 deletion virus mutant (∆M27-23 
MCMV) is almost not affected in cell culture (18-21) but is highly attenuated in vivo (18, 21). 24 
Using a forward genetic screening approach, we identified pM27 to be an IFN antagonist 25 
targeting STAT2 (21) and thereby abrogating the induction of IFN target genes (21, 22). 26 
Consistently, replication of ∆M27-MCMV is highly susceptible to IFNs in cell culture (21, 27 
23). pM27 acts by recruiting cellular DDB1-containing ubiquitin ligase complexes and to 28 
proteasomally degrade STAT2 (23). Like MCMV, HCMV also encodes a yet unknown 29 
protein inducing proteasomal degradation of STAT2 (24). 30 
Here, we extend our analysis to the interplay between MCMV and further STAT transcription 31 
factors present in CMV target cells. Unexpectedly, we found prolonged STAT1 Y-32 
phosphorylation and seemingly autonomous STAT3 phosphorylation as consequence of viral 33 
JAK-STAT inhibition instead of being a hallmark of STAT activation. 34 
35 
 5 
Material and Methods: 1 
Cells and cytokines 2 
NIH3T3 (ATCC CRL-1658), RAW 264.7 (ATCC TIB-71), M2-10B4 (kindly provided by 3 
Brendan Marshall [Medical College of Georgia, USA]), mHTC-K2 (25), STAT3flox/flox, crisis 4 
immortalized IFNAR1- (26), respective C57BL/6 control fibroblasts, STAT3- (27), JAK2- 5 
(28), IL-6- and primary IL-10-deficient (prepared as described (29)) fibroblasts were grown in 6 
Dulbecco's modified eagle medium (D-MEM) with 10% (vol/vol) foetal bovine serum (Gibco 7 
[Invitrogen]), streptomycin, penicillin and 2 mM glutamine. 8 
IFNs (mouse IFNα (#12100-1) and mouse IFNγ (#12500-1)) were purchased from PBL 9 
Biomedical Laboratories, New Jersey, USA. If not stated otherwise, cells were treated with 10 
500 U/ml IFN. Hyper-IL-6 has been described previously (30). 11 
 12 
Viruses, infection conditions and virus titration 13 
Preparation, purification and titration of MCMV stocks was done as described previously (21, 14 
26, 31). wt-MCMV and ∆M27-MCMV have been described previously (21). For the 15 
construction of ∆m157-MCMV:mCherry, a frt-site-flanked fragment encompassing the 16 
HCMV-derived major IE promoter/enhancer (MIEP) in front of the mCherry gene was 17 
introduced into a recombinant MCMV bacterial artificial chromosome (which already 18 
harbored a frt site instead of the m157 CDS) by flp-mediated recombination. UV inactivation 19 
was conducted with indicated J/m2 doses of UV irradiation in a CL-1000 UV cross-linker 20 
(UVP). 21 
 22 
Electromobility shift assay (EMSA) 23 
Extraction of fractionated EMSA lysates and the EMSA assay was performed as described 24 
(26). Briefly, cells were lysed in cytosolic extraction buffer (20 mM Hepes, pH 7.4, 10 mM 25 
KCl, 0.2% [vol/vol] NP-40, 0.1 mM EDTA, 10% [vol/vol] glycerol, 0.1 mM Na-vanadate, 0.1 26 
mM PMSF, 1 mM dithiothreitol (DTT), Complete® protease inhibitors [Roche, Mannheim, 27 
Germany]). The extracts were centrifuged at 16,000 g for 16 s at 4°C, the supernatants were 28 
collected, centrifuged for 10 min and used as cytosolic extracts for EMSA. The pellets were 29 
washed in PBS and suspended in nuclear extraction buffer (20 mM HEPES, pH 7.6, 420 mM 30 
KCl, 0.1 mM vanadate, 20% [vol/vol] glycerol, 1 mM EDTA, 0.1 mM PMSF, 1 mM DTT, 31 
Complete® protease inhibitors [Roche, Mannheim, Germany]). After incubation on ice for 25 32 
min the extracts were centrifuged at 16,000 g for 25 min at 4°C, and the supernatants were 33 
used as nuclear extracts. Both extracts were frozen immediately in liquid nitrogen until final 34 
 6 
use. Nuclear or cytosolic lysates were incubated with 1 ng (~50 000 cpm) of (32P)-labelled 1 
M67 GAS (32) probe for 20 min at room temperature. The DNA-protein complexes were 2 
separated on 4.7% (vol/vol) polyacrylamide, 22.5 mM TrisHCl, 22.5 mM borate and 50 µM 3 
EDTA gels, fixed and finally visualized by autoradiography. Supershifts were performed with 4 
a STAT1 antibody (Santa Cruz). 5 
 6 
Immunoblotting 7 
Cells were lysed in RIPA+-buffer (50 mM Tris-HCl, 150 mM NaCl, 1% [vol/vol] IGEPAL, 8 
1% Na-Deoxycholate [weight/vol], 0.1% [weight/vol] SDS, 1 mM DTT, 0.2 mM 9 
phenylmethylsulfonyl fluoride (PMSF), 1 µg/ml leupeptin, 1 µg/ml pepstatin, 50 mM NaF, 10 
0.1 mM Na-vanadate with Complete® protease inhibitors [Roche] pH 7.5). Samples were 11 
normalized according to Bradford protein staining and equal amounts were subjected to 12 
denaturing SDS-PAGE. Gels were blotted on nitrocellulose membranes (GE Healthcare) and 13 
probed with indicated antibodies. The same membrane was used and consecutively stripped 14 
with reblot solution (Millipore). The following antibodies were used: α-β-actin from Sigma-15 
Aldrich; α-STAT3 (K-15), α-STAT3 (C-20), α-STAT3 (H-190), α-STAT3 (F-2), α-phospho-16 
Y705 STAT3 (B-7), α-STAT1(E-23), α-IκBα (C-21), and α-IRF-1 (M-20) from Santa Cruz; 17 
α-phospho-Y701 STAT1, α-phospho-S727 STAT1, α-phospho-S727 STAT3 and α-Lamin 18 
A/C from Cell Signaling, α-SOCS3 (ab16030) from Abcam. α-pp89-IE1 (Croma101) and α-19 
pM45 were provided by Stipan Jonjić, University of Rijeka, Croatia. The actual MCMV 20 
antigen of the α-pM45 was defined by co-immuno-precipitation and mass-spectrometry by 21 
Gabriela E. Androsiac, HHU Düsseldorf, Germany. Quantification of immunoblot signals was 22 
conducted using a Fusion FX7 (Vilber Lourmat). 23 
 24 
Luciferase Assay 25 
For reporter gene assays, a NIH3T3-derived cell line harbouring a GAS luciferase vector was 26 
selected. To do so, a fragment comprising the promoter/enhancer sequence and the fire fly 27 
(Photinus pyralis) luciferase gene from the pTA-GAS construct (Clontech) was sub-cloned 28 
into a pGene vector backbone conferring Zeocine resistance (Invitrogen). Cells were induced 29 
with 100 U/ml of the indicated recombinant mouse IFN. Luciferase activity was measured 30 
using the luciferase reporter gene assay, high sensitivity according to the manufacturer’s 31 
instructions (Roche) using a microplate luminometer (model LB 96V; Berthold). 32 
 33 
Northern blot analysis of specific transcripts 34 
 7 
Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen). Total RNA was 1 
subjected to MOPS gel electrophoresis and transferred to nylon membranes using the 2 
TurboBlotter (Schleicher and Schuell). Probes were prepared by PCR with gene-specific 3 
primers (Table 1) and digoxigenin-labelled dUTP (Roche) for detection of indicated 4 
transcripts. Hybridization and detection were performed as described in Roche manuals. 5 
 6 
Analysis of nuclear translocation of STAT1 7 
For visualization of IFN-γ-induced nuclear translocation of STAT1, we constructed a STAT1-8 
EGFP fusion protein. Based on the expression vector pIRES2EGFP-mSTAT1HA (STAT1HA 9 
amplified using primers mSTAT1-1 CGGCTAGCATGTCACAGTGGTTCGAGCTTC and 10 
mSTAT1-HA2 11 
CGCTCGAGTTAAGCGTAATCTGGAACATCGTATGGGTATACTGTGCTCATCATAC12 
TGTCAAATTC with total RNA of BALB/c MEF as template), we generated a PCR product 13 
using the primers mSTAT1-1 and HA-EGFP-2 14 
CGGAATTCGAGCGTAATCTGGAACATCGTATGGG. This fragment was digested with 15 
NheI and EcoRI to clone it in two steps into pEGFP-N1, resulting in STAT1-EGFP. NIH3T3 16 
fibroblasts were transfected (Superfect, Qiagen) with a STAT1-EGFP expression vector. 24 h 17 
post transfection, cells were mock-treated or infected with ∆m157-MCMV:mCherry (2 18 
PFU/cell). 16 h post infection, cells were incubated with 200 U/ml IFN-γ for 45 min. After 19 
IFN-treatment, cells were fixed using 4% (weight/vol) paraformaldehyde-PBS for 20 min. 20 
IFNγ-induced nuclear translocation of STAT1-EGFP was visualized by fluorescence 21 
microscopy using a Leica DM IL LED Fluo and LAS V4.0. 22 
 23 
Chromatin immuno-precipitation (ChIP) 24 
Crosslinking was achieved by adding formaldehyde (1% [vol/vol] final concentration) to 25 
cells. After 10 min, crosslinking was stopped by addition of glycine (125 mM final 26 
concentration). Cells were washed twice with ice cold PBS and subsequently detached from 27 
the cell culture plates by scraping in ice cold Na-butyrate containing PBS. Cells were washed 28 
in buffer 1 (0.5% [vol/vol] Triton-X-100, 20 mM EDTA, 0.5 mM EGTA, 20 mM HEPES pH 29 
7.5 and 20 mM Na-butyrate) and buffer 2 (400 mM NaCl, 2 mM EDTA, 0.5 mM EGTA, 20 30 
mM HEPES pH 7.5 and 20 mM Na-butyrate). Cells were lysed in lysis buffer (150 mM NaCl, 31 
25 mM Tris pH 7.5, 5 mM EDTA, 1% [vol/vol] Triton-X-100, 0.1% [weight/vol] SDS, 0.5% 32 
[weight/vol] Na-deoxycholate, 1 mM PMSF, 10 mM Na-butyrate and Complete protease 33 
inhibitors (Roche). Lysates were sonicated (5 cycles [2 min each]; amplitude 30; cycle 0.5 on 34 
 8 
ice in a Sartorius Labsonic P) and subsequently cleared by centrifugation. Supernatants were 1 
pre-cleared by addition of protein G sepharose (PGS) in presence of 100 µg/l salmon sperm 2 
DNA and 500 µg/l BSA. After the pre-clearing procedure, an aliquot was stored (‘input’). 3 
Precipitation was performed over night at 4°C using a STAT1-specific antibody (E-23; Santa 4 
Cruz). Immune complexes were precipitated using PGS (1-2 h at 4°C). Afterwards, the 5 
sepharose was washed twice with RIPA buffer (150 mM NaCl, 50 mM Tris pH 8.0, 0.1% 6 
[weight/vol] SDS, 0.5% Na-deoxycholate and 1% [vol/vol] NP-40), twice with high salt 7 
buffer (500 mM NaCl, 50 mM Tris pH 8.0, 0.1% [weight/vol] SDS and 1% [vol/vol] NP-40), 8 
twice with LiCl buffer (25 mM LiCl, 50 mM Tris pH 8.0, 0.5% [weight/vol] Na-deoxycholate 9 
and 1% [vol/vol] NP-40) and twice with TE buffer (10 mM Tris pH 8.0 and 1 mM EDTA). 10 
Immune complexes were eluted using elution buffer (2% [weight/vol] SDS, 0.1 M NaHCO3 11 
and 10 mM DTT). Crosslinking was reversed by addition of 0.05 volume of 4 M NaCl and 12 
subsequent incubation for 4 h at 65°C. Proteins were digested using Proteinase K. After 13 
standard phenol/chloroform extraction, ethanol precipitation and washing with 70% (vol/vol) 14 
ethanol, immune-precipitated DNA was analysed by PCR using previously described primers 15 
(33) specific for the mouse irf-1 promoter (5’- AGCACAGCTGCCTTGTACTTCC-3’ and 5’-16 
CTTAGACTGTGAAAGCACGTCC-3’) yielding a 229 nucleotide long product. 17 
18 
 9 
Results: 1 
MCMV abrogates STAT1 signalling downstream of intact STAT1 Y701 phosphorylation, 2 
nuclear translocation and DNA-binding 3 
Intrigued by the central role of STAT1 for type I and type II IFN signalling, we investigated 4 
the interplay between MCMV and STAT-activation by IFNs. In clear contrast to STAT2, 5 
which is rapidly degraded upon MCMV infection (21, 23), STAT1 protein amounts remained 6 
stable in MCMV-infected cells (Fig. 1A). STAT1 Y701 phosphorylation was virtually absent 7 
in untreated cells but became strongly induced upon exposure to IFNγ (Fig. 1A). A 8 
comparable IFNγ-induced STAT1 phosphorylation was also evident in MCMV-infected cells 9 
(Fig. 1A) indicating that IFNGR proximal events of JAK-STAT1 signalling are not affected 10 
by MCMV-encoded IFN antagonists. Nuclear translocation of STAT1 was also not inhibited 11 
by MCMV since equal amounts of phosphorylated STAT1 were detected in nuclear lysates of 12 
IFNγ-incubated MCMV-infected cells and mock control cells (Fig. 1A, right panel). 13 
Consistently, the nuclear translocation of transiently transfected GFP-tagged STAT1 was not 14 
compromised upon MCMV infection (Fig. 1B). The analysis of the DNA-binding capacity of 15 
STAT1 by electro-mobility shift assay (EMSA) revealed that STAT1:STAT1 homodimers 16 
retained their capacity to bind to gamma activated sequence (GAS) DNA elements after 17 
MCMV infection - irrespective of M27 coding capacity (Fig. 1C). Chromatin 18 
immunoprecipitation (ChIP) experiments confirmed the intact ability of STAT1 to bind to 19 
endogenous GAS DNA elements (here the irf-1 promoter) in MCMV-infected cells upon 20 
IFNγ exposure (Fig. 1D). To test the ability of MCMV to antagonize GAS-dependent gene 21 
expression, we constructed a stable MCMV-permissive NIH3T3 cell line harbouring the 22 
firefly (Photinus pyralis) luciferase reporter gene under the control of a minimal promoter 23 
and a GAS enhancer element. In mock-infected cells, IFNγ strongly induced luciferase 24 
activity, but the response was significantly inhibited upon MCMV infection - again 25 
irrespective of M27 coding capacity (Fig. 1E). To rule out that this effect is influenced by 26 
previously observed effects of CMV infections on gene expression derived from reporter 27 
plasmids (34), we studied the ability of MCMV to counteract the IFNγ-dependent induction 28 
of endogenous IRF-1 mRNA by northern blotting. 4 h of MCMV infection already sufficed to 29 
antagonize IFNγ-induced IRF-1 transcription (Fig. 1F). These results demonstrate that 30 
MCMV abrogates IFNγ-induced gene expression without compromising overall STAT1 31 
protein amounts, receptor-proximal Y701 STAT1 phosphorylation, nuclear translocation of 32 
STAT1 or the capability to bind to DNA - largely confirming previous reports (35). 33 
Additionally, our results reveal that this inhibition is not influenced by pM27, documenting 34 
 10 
the existence of at least one additional MCMV-encoded antagonist of JAK-STAT signal 1 
transduction. 2 
 3 
MCMV gene expression induces IFNAR1-independent STAT3 phosphorylation 4 
Given that STAT1 and STAT3 are highly homologous proteins (53% identical and 72% 5 
similar) and that STAT3 transduces signals of pro- as well as anti-inflammatory cytokines 6 
that play a crucial role in CMV immune control and pathogenesis (11-14), we extended our 7 
analysis to STAT3. In contrast to STAT1, a basal STAT3 Y705 phosphorylation was 8 
frequently (depending on exposure time of the films) observed in untreated, mock-infected 9 
cells. Nevertheless, we observed a substantial increase of STAT3 Y705 phosphorylation upon 10 
MCMV infection (Fig. 2A-C). Surprisingly, global STAT3 protein amounts simultaneously 11 
declined in MCMV-infected cells as revealed by two different STAT3-specific antibodies 12 
recognizing different parts of STAT3 (Fig. 2A-C). Y705 phosphorylation by MCMV was 13 
invariably evident in a variety of cells including NIH3T3, M2-10B4, mHTC-K2 and others 14 
(see Fig. 2A-F and data not shown). The extent of the virus-induced Y705 phosphorylation 15 
was comparable to the effect elicited by treatment with 20 ng/ml Hyper-IL-6 - a STAT3-16 
activating designer cytokine generated by fusion of the coding sequence of IL-6 to the 17 
extracellular domain of the gp80 subunit of the IL-6 receptor. Conversely, the MCMV-18 
induced decline in overall STAT3 amounts was not observed in Hyper-IL-6 treated cells 19 
suggesting that the phosphorylation event does not preclude STAT3 recognition by the used 20 
antibodies (C-20 and K-15). To confirm the detected protein band to represent truly STAT3, 21 
we performed an experiment in STAT3-deficient cells. We observed STAT3 phosphorylation 22 
upon MCMV infection in STAT3-positive cells, but no signal was detectable in STAT3-23 
deficient cells (Fig. 2B). Since the respective membranes were probed in a sequential manner, 24 
STAT3 was also detected on separate membranes by different antibodies in parallel to ensure 25 
that such procedure does not mask secondary STAT3 detection. We reproduced increased 26 
levels of Y705 phosphorylation despite an overall reduction of STAT3 protein amounts in 27 
MCMV-infected cells (Fig. 2C). The decrease of STAT3 and the parallel increase of 28 
phosphorylated STAT3 was quantified (Fig. 2D). An increasing MCMV infection dose was 29 
directly positively correlated with STAT3 Y705 phosphorylation as well as reduction of the 30 
overall STAT3 protein amount (Fig. 2E). 31 
Among other cytokines and growth factors, IFNα is known to induce STAT3 phosphorylation 32 
(36). This effect was also observed in MCMV-permissive NIH3T3 cells (Fig. 2F). Since 33 
MCMV infection initially induces type I IFN production (31), we used IFNAR1-deficient 34 
 11 
cells to test if the observed STAT3 phosphorylation is caused by type I IFN. STAT3 1 
phosphorylation and reduction of STAT3 protein amounts were observed with almost 2 
congruent kinetics in IFNAR1-deficient and identically immortalized C57BL/6 fibroblasts 3 
(Fig. 2G), indicating that both effects on STAT3 are IFNAR1-independent. 4 
To analyse if viral gene expression is required for STAT3 modulation, NIH3T3 cells were 5 
infected with MCMV virions which had been inactivated with grading UV doses (250 - 6 
10,000 J/m2). Subsequently, STAT3 phosphorylation and global STAT3 protein amounts 7 
were assessed by immunoblot. UV-inactivation of viral gene expression, as documented by 8 
pp89-IE1 detection, abrogated STAT3 phosphorylation and reduction (Fig. 2H), indicating 9 
that cytomegaloviral gene expression is essential for the observed modulation of STAT3. 10 
We also detected STAT3 phosphorylation upon reversible application of protein synthesis 11 
inhibitor Cycloheximide (CHX) followed by Actinomycin D (ActD) inhibition of 12 
transcription leading to MCMV gene expression restricted to immediate early (IE) gene 13 
products (37). However, this result cannot be interpreted as a proof for the responsibility of 14 
viral IE genes due to similar drug-induced changes in STAT3 phosphorylation levels in UV-15 
MCMV as well as mock-infected cells (data not shown). A previously described fibroblast 16 
cell line stably transfected with the IE gene region encompassing the respective HindIII 17 
fragment of MCMV and thus being able to complement the growth of MCMV mutants 18 
lacking the essential gene ie3 (38), did not exhibit overt STAT3 phosphorylation or reduced 19 
STAT3 protein amounts in comparison to parental NIH3T3 cells (data not shown), suggesting 20 
that ie gene expression is not sufficient for the observed changes of STAT3. 21 
To evaluate whether MCMV late gene expression is required for the effects on STAT3, we 22 
infected cells in the presence of ganciclovir (GCV) - a drug which interferes with MCMV 23 
DNA replication and thereby strongly reduces the accompanying viral late gene expression. 24 
Late gene expression was neither essential for the phosphorylation of STAT3 nor for the 25 
reduction of STAT3 overall amounts (Fig. 2I). Taken together, these results reveal that (a) 26 
MCMV IE- and/or early-expressed gene product(s) induce(s) a sustained STAT3 27 
phosphorylation and simultaneously reduce(s) STAT3 overall amounts. 28 
 29 
The MCMV-induced STAT3 Y705 phosphorylation occurs independent of IL-6, IL-10, gp130 30 
and JAK2 and is restricted to infected cells  31 
As mentioned above, MCMV induces cytokines like IL-6 and IL-10, which mainly signal via 32 
STAT3. Therefore, we tested if these cytokines are involved in the MCMV-induced STAT3 33 
Y705 phosphorylation. Fibroblasts deficient for IL-6 and IL-10, respectively, both exhibited 34 
 12 
STAT3 phosphorylation upon MCMV infection (Fig. 3A), indicating that these interleukins 1 
are not essential for the observed phosphorylation. Since JAK2 is known to be crucial for the 2 
signalling of a variety of cytokine receptors (28, 39), we assessed JAK2-deficient fibroblasts, 3 
but again we observed STAT3 phosphorylation upon MCMV infection (Fig. 3A). However, 4 
we could not exclude the possibility that STAT3 phosphorylation results from redundant 5 
signalling via several receptors. Paralleling STAT3 phosphorylation, the reduction of the 6 
overall STAT3 protein amount was also evident in the three gene-deficient cells and the 7 
control fibroblasts (Fig. 3A). 8 
STAT3 can be phosphorylated by cytokines via receptor bound janus kinases but also by 9 
growth factors via receptor tyrosine kinases (RTKs) and by cytoplasmic kinases like c-Src 10 
(40) and BCR-ABL (41, 42). Several STAT3-activating cytokines signal via a heterodimeric 11 
receptor complex composed of a cytokine-specific subunit and the gp130 signalling module. 12 
Soluble gp130-Fc blocks gp130-dependent IL-6 signalling and to a lesser extent LIF and 13 
OSM signalling (43). Therefore, we used commercially available soluble gp130-Fc, to test the 14 
involvement of gp130 in MCMV-induced STAT3 phosphorylation. As expected, soluble 15 
gp130 blocked Hyper-IL-6-dependent STAT3 activation, but the STAT3 phosphorylation by 16 
MCMV was not impaired (data not shown). 17 
Next, we transferred conditioned medium (sterile-filtered or UV-inactivated) from MCMV-18 
infected NIH3T3 cells (which exhibited substantial STAT3 phosphorylation) to uninfected 19 
fibroblasts and RAW 264.7 macrophages, respectively. Conditioned medium did not induce 20 
STAT3 phosphorylation above background in fibroblasts or RAW cells (Fig. 3B). 21 
Subsequently, we conducted transwell experiments in which MCMV-infected and uninfected 22 
cells continuously share the same medium. Again, STAT3 phosphorylation was only 23 
observed in infected cells but not in uninfected bystander cells (Fig. 3C), suggesting that the 24 
STAT3 Y705 phosphorylating principle is restricted to infected cells and not transferable to 25 
neighbouring cells when MCMV transmission is prevented. From these data we assume that 26 
STAT3 phosphorylation does not require a secreted factor released from infected cells, 27 
although we cannot formally rule out the implication of membrane bound cytokines (like for 28 
example the tumour necrosis factor (TNF) superfamily member LIGHT which has been 29 
shown to induce STAT3 phosphorylation (44)). 30 
Under standard (non-serum-starved) culture conditions, cells are constantly exposed to 31 
growth factors present in the foetal bovine serum contained in the cell-culture media. Several 32 
growth factors (e.g. basic fibroblast growth factor (45) and insulin-like growth factor I (46)) 33 
have been demonstrated to induce STAT3 phosphorylation. We therefore tested if and how 34 
 13 
such growth factors influence the MCMV-induced STAT3 phosphorylation. Even though 1 
STAT3 phosphorylation was restricted to cells being MCMV-infected and was not 2 
transmitted to bystander cells (see above), we found that increasing foetal bovine serum 3 
(FBS) present in the cell culture medium concentration-dependently enhanced STAT3 4 
phosphorylation in MCMV-infected cells (Fig. 3D - for a discussion of this finding see 5 
below). 6 
Taken together, MCMV induces STAT3 phosphorylation in infected cells by an IFNAR1-, 7 
IL-6-, IL-10-, gp130- and JAK2-independent principle which is restricted to infected cells. In 8 
addition, growth factors present in the cell culture media (e.g. FBS) have the potency to 9 
further enhance STAT3 phosphorylation in MCMV-infected cells. 10 
 11 
MCMV interferes with STAT1 and STAT3-dependent gene expression 12 
Based on our finding that tyrosine phosphorylated STAT1 molecules are transcriptionally 13 
inert in MCMV-infected cells (Fig. 1), we raised the question if MCMV-induced Y705 14 
phosphorylated STAT3 is actually active in terms of target gene expression. To this end we 15 
chose the canonical target gene SOCS3 encoding an immediately responsive and highly 16 
sensitive surrogate marker protein of STAT3 function. Cells were infected with MCMV and 17 
24 h post infection treated with Hyper-IL-6 and IFNγ, respectively. Interestingly, despite 18 
efficient induction of Y705 phosphorylated STAT3 in MCMV-infected cells, we did not 19 
observe the expected increase of SOCS3 amounts. On top of that, an additional stimulation 20 
with Hyper-IL-6 or IFNγ, which strongly induces SOCS3 in mock cells, failed to induce 21 
SOCS3 in MCMV-infected cells (Fig. 4A). Adequate MCMV infection was documented by 22 
detection of pp89-IE1 and equal protein loading by detection of β-actin. As expected, MCMV 23 
infection resulted in reduced STAT3 protein amounts (Fig. 4A). 24 
To test if the blockade of the SOCS3 response is specific or part of a general inhibition and 25 
whether it is executed on transcriptional level or acts post-transcriptionally, we performed 26 
northern blot experiments. We found that MCMV infection drastically inhibited the induction 27 
of SOCS3, SOCS1, IRF-1 and cEBPδ transcripts by IFNγ and the induction of multiple 28 
STAT3 target genes including SOCS3, IRF-1, cEBPδ, JunB and c-Myc by Hyper-IL-6 (Fig. 29 
4B). 30 
In this context, it is noteworthy that it is well documented that an auto-regulative STAT3 31 
circuit exists since STAT3 gene transcription is STAT3-dependent (47-49). Thus, the decline 32 
of STAT3 protein amount might represent a consequence of the cytomegaloviral disruption of 33 
canonical STAT3-dependent signal transduction and gene expression. Therefore, we tested 34 
 14 
the expression of STAT3 mRNA and found it to be significantly reduced upon MCMV 1 
infection (Fig. 4B). In summary, MCMV interferes with STAT1 and STAT3 signal 2 
transduction, leading to impaired target gene induction. 3 
To reach the maximal rate of transcriptional activity, certain STAT molecules (including 4 
STAT1 and STAT3) require additional phosphorylation of serine residue 727 (50). Since our 5 
data uncover a MCMV-encoded inhibition of STAT1 and STAT3 target gene expression at a 6 
step beyond tyrosine phosphorylation, we assessed Ser727 phosphorylation of STAT1 and 7 
STAT3 in MCMV-infected cells upon treatment with IFNγ or Hyper-IL-6. We found that the 8 
IFNγ-induced Ser727 phosphorylation was not inhibited by MCMV (Fig. 5). MCMV 9 
infection did also not significantly change the level of constitutive Ser727 STAT3 10 
phosphorylation in unconditioned cells (Fig. 5). Nevertheless, the Hyper-IL-6-induced 11 
increase in Ser727 phosphorylation of STAT3 was to a certain extent reduced in MCMV-12 
infected cells (irrespective of M27 coding capacity) compared to mock-infected cells or cells 13 
infected with UV-irradiated MCMV (Fig. 5). We interpret this minor change in Ser727 14 
phosphorylated STAT3 in MCMV-infected cells as indirect consequence of the reduced 15 
overall STAT3 amounts. 16 
 17 
MCMV infection prolongs IFNγ-induced STAT1 Y701 phosphorylation 18 
JAK-STAT signalling pathways are highly auto-regulative. Upon activation, negative feed-19 
back regulation is initiated by de novo expression of proteins like SOCS1, SOCS3, PIAS or 20 
Usp18 which terminate the signalling process. Having demonstrated that MCMV infection 21 
antagonizes SOCS1 and SOCS3 induction upon IFNγ and Hyper-IL-6 stimulation, we raised 22 
the question whether the MCMV-encoded inhibitor, which acts on the level of transcriptional 23 
activation after effected phosphorylation, would prevent the expression of negative feed-back 24 
regulators and thereby counterintuitively prolong IFNγ-induced STAT1 phosphorylation. To 25 
test this hypothesis, we pulse stimulated infected or non-infected cells for a short period (30 26 
min) with IFNγ. Afterwards, we vigorously washed the cells to remove the IFNγ and then 27 
followed the slope of declining STAT1 phosphorylation levels over a period of 8 h. As shown 28 
in Fig. 6, STAT1 phosphorylation was virtually undetectable in untreated cells but readily 29 
observed after adding IFNγ. In mock infected cells, STAT1 phosphorylation declined within 4 30 
h. Conversely, in MCMV-infected cells a substantial amount of phosphorylated STAT1 was 31 
still apparent after 8 h. M27 coding capacity did not affect this prolongation of STAT1 32 
phosphorylation. We concluded that MCMV interferes with IFNγ-induced gene expression on 33 
the transcriptional level downstream of STAT1 Y701 phosphorylation resulting in abrogation 34 
 15 
of the induction of the negative feedback loop (e.g. SOCS1 expression) leading to prolonged 1 
STAT1 phosphorylation upon incubation with IFNγ. 2 
 3 
Neither pIE1pp89 nor pM27 are essential for the cytomegaloviral STAT3 regulation 4 
HCMV IE1-pp72 has been described as inhibitor of IFN-JAK-STAT signalling which 5 
antagonizes ISRE signal transduction and simultaneously induces GAF-like responses (51, 6 
52). Despite the limited primary sequence conservation between HCMV IE1-pp72 and 7 
MCMV IE1-pp89 (~22% identity and ~42% similarity within a ~190 amino acid stretch 8 
[residues 23-197 in HCMV IE1-pp72 and 33-210 in MCMV pp89-IE1, respectively]), the 9 
MCMV homolog IE1-pp89 was found to co-precipitate with human STAT2 (53) defining 10 
MCMV-pIE1 as potential candidate for a STAT-specific IFN antagonist. Therefore, we tested 11 
if the STAT3 phosphorylation, reduction of the overall STAT3 amount and the inhibition of 12 
target gene expression are preserved in cells infected with an MCMV mutant lacking the ie1 13 
coding capacity. All three effects were found to be independent of ie1 (Fig. 7A). 14 
Besides pIE1-pp72, the only other known cytomegaloviral antagonist of JAK-STAT signal 15 
transduction is pM27 (54). Consequently, we tested if M27 is required for STAT3 16 
modulation. But ∆M27-MCMV was also fully capable to stimulate STAT3 phosphorylation, 17 
reduced overall STAT3 amounts and antagonized SOCS3 expression (Fig. 7B). These results 18 
rule out an essential contribution of M27 to the herein described regulation of STAT3 signal 19 
transduction and the accompanying inhibition of target gene induction. 20 
 21 
MCMV reveals a dynamic equilibrium of STAT3 activation and deactivation 22 
MCMV interferes with STAT1- and STAT3-dependent gene expression in a strikingly similar 23 
manner. In both cases, the expression of target genes is antagonized on the transcriptional 24 
level despite the nuclear presence of Tyr-phosphorylated STATs. The lack of target gene 25 
expression includes the well-known negative feedback regulators SOCS1 and SOCS3, 26 
explaining the exaggerated tyrosine phosphorylation. Nevertheless, STAT1 phosphorylation 27 
is prolonged but requires the external stimulus IFNγ, whereas STAT3 phosphorylation is 28 
seemingly ‘autonomous’. How can this apparent difference be reconciled? We hypothesize 29 
that cell culture media including FBS contains stimuli like growth factors which induce low-30 
level of `constitutive` STAT3 Y705 phosphorylation. These growth factors induce STAT3 31 
phosphorylation which stimulates gene expression including the STAT3-dependent mediators 32 
of the negative feedback (e.g. SOCS3) constantly balancing phosphorylated STAT3 at low 33 
level. Consistently, cre-recombinase induced SOCS3 excision has been found to lead to 34 
 16 
increased levels of tyrosine-activated STAT3 (55). To test if such a low level STAT3 1 
activation exists in MCMV-permissive cells, we used the broad spectrum phosphatase 2 
inhibitor sodium vanadate to interfere with STAT3 de-phosphorylation. A 15 min treatment 3 
leading to a blockade of cellular phosphatases already induced accumulation of 4 
phosphorylated STAT3 eventually resulting in SOCS3 protein induction (Fig. 8A). This 5 
finding indicates that a fine-tuned dynamic equilibrium of STAT3 phosphorylation, gene 6 
expression of negative feed-back regulators and subsequent dephosphorylation of STAT3 7 
exists in MCMV-permissive cells and that uncoupling of activation and subsequent negative 8 
feed-back inhibition results in accumulating phospho-STAT3. We made further use of this 9 
sodium-vanadate-mediated uncoupling to induce a long-term ‘tyrosine phosphorylation state’ 10 
and the accompanied SOCS3 induction in cells. Consistent with general inhibition of STAT3 11 
target gene expression, MCMV-infection also precluded SOCS3 and IRF-1 protein expression 12 
upon long-term sodium-vanadate incubation (Fig. 8B). 13 
Taken together, the herein described MCMV-encoded STAT3 inhibition reveals the existence 14 
of a dynamic equilibrium of STAT3 by uncoupling phosphorylation and induction of 15 
mediators of the negative feed-back loop. 16 
17 
 17 
Discussion: 1 
We found that MCMV induces seemingly cytokine-autonomous STAT3 phosphorylation. 2 
STAT3 phosphorylation is essential for STAT3 activation and thus considered to constitute a 3 
faithful surrogate marker for transcriptional STAT3 activity. Although STAT3 is known to 4 
stimulate its own transcription (47-49), STAT3 phosphorylation in MCMV-infected cells was 5 
accompanied by a reduction of overall STAT3 amounts. This contradiction led to the finding 6 
that even a strong external stimulation like Hyper-IL-6 failed to induce all tested STAT3 7 
target genes in MCMV-infected cells, documenting the existence of a potent MCMV-encoded 8 
antagonist of STAT3 signal transduction. A comprehensive molecular analysis revealed that 9 
MCMV interferes with STAT1- and STAT3-dependent signalling after effected tyrosine 10 
phosphorylation, thereby also compromising the intrinsic negative feedback loop otherwise 11 
executed by proteins like SOCS1 and SOCS3. Due to the lack of these negative regulators, 12 
the dynamic equilibrium of STAT phosphorylation and subsequent inactivation is uncoupled 13 
upon MCMV infection, leading to the accumulation of transcriptional inactive phospho-14 
STAT3. The on-rate of the intrinsic equilibrium is influenced by growth factors present in the 15 
cell culture medium and especially the FBS. Therefore, increasing FBS concentrations dose-16 
dependently increase STAT3 phosphorylation in MCMV-infected cells. 17 
In contrast to STAT3, which is activated by a broad variety of cytokines, interleukins and 18 
growth factors, only very few cytokines e.g. IFNs and IL-35 (56) critically rely on STAT1. 19 
Therefore, STAT1 phosphorylation is not induced by constituents of serum and untreated 20 
cells virtually do not phosphorylate STAT1 and therefore no accumulation can be observed 21 
upon MCMV infection alone. Nevertheless, once the cell encounters STAT1-activating 22 
cytokines like IFNγ, STAT1 phosphorylation is also prolonged in MCMV-infected cells, yet 23 
it remains transcriptionally inert. 24 
 25 
STAT tyrosine phosphorylation - a true hallmark for transcriptional activity? 26 
Under normal conditions, phosphorylation of STAT1 and STAT3 at Y701 and Y705, 27 
respectively, is undoubtedly crucial for STAT activation. Since highly specific antibodies are 28 
available, the determination of the phosphorylation status represents a widely applied way to 29 
assess activity of STATs. Our data uncover a biological condition (i.e. virus infection) which 30 
challenges the view that tyrosine phosphorylated STATs are necessarily transcriptional active. 31 
This example of stalled STAT transcription complexes demonstrates the necessity to conduct 32 
further experiments to unequivocally prove the transcriptional activity of tyrosine 33 
phosphorylated STAT molecule species. Textbook schemes usually simplify JAK-STAT 34 
 18 
signal transduction by only depicting STAT factors binding to respective DNA enhancer 1 
elements directly resulting in target gene expression. Apparently, the process of 2 
transcriptional initiation and transcription by STATs is a highly regulated process requiring 3 
precisely choreographed activity of multiple proteins like co-activators, the mediator complex 4 
and the RNA polymerase II complex (see for example (57, 58)). Our data indicate that 5 
MCMV interferes with at least one factor involved in this step of regulation. 6 
 7 
Implications for ∆M27-MCMV pathogenesis 8 
We have previously described the MCMV-encoded protein pM27 as potent STAT2-specific 9 
IFN antagonist (21-24) which interferes with type I IFN signal transduction by inducing rapid 10 
proteasomal degradation of STAT2 via recruiting STAT2 to DDB1-containing ubiquitin 11 
ligase complexes (23). In absence of M27, MCMV hardly interferes with IFNα-dependent 12 
gene expression (21), strongly suggesting that pM27 is essential and sufficient to antagonize 13 
formation of functional ISGF3 (STAT2:STAT1:IRF9) complexes. Here, we have 14 
characterized a second M27-independent MCMV-encoded antagonism targeting both STAT1 15 
and STAT3 signalling. Together both inhibitors preclude type I and type II IFN responses. 16 
The presence of IFNα-dependent gene expression observed in ∆M27-MCMV-infected cells 17 
together with the pronounced IFN susceptibility of ∆M27-MCMV in vitro and in vivo (21-23) 18 
indicate that the herein described second MCMV-encoded IFN antagonist does not (or only to 19 
a limited degree) affects ISGF3 complexes and that both MCMV-encoded inhibitors possess 20 
non-redundant functions. 21 
∆M27-MCMV replication is over-proportionally susceptible to IFNα, but replication is 22 
almost completely abrogated in IFNγ-conditioned cells (21). This might be in part explained 23 
by IFNγ-dependent STAT2 phosphorylation (21, 59, 60) but IFNγ-induced Y689 STAT2 24 
phosphorylation is less pronounced compared to stimulation by type I IFNs, yet the antiviral 25 
effect of IFNγ is more potent (21). Our data reveal that phosphorylated STAT3 and STAT1 26 
(in presence of IFNγ) accumulate in MCMV-infected cells but remain transcriptionally inert. 27 
In the wt-MCMV infection scenario, STAT2-dependent gene expression is abrogated by 28 
pM27-dependent STAT2 degradation. Upon ∆M27-MCMV infection, increased and 29 
prolonged tyrosine phosphorylation of STAT3 and STAT1, respectively, join STAT2 which 30 
seems to bypass the second inhibitor of STAT1 signalling. Together these STATs induce an 31 
‘overshooting’ antiviral state via trans-signalling from IFNγ to ISRE-driven ISGs. 32 
 33 
MCMV effects on ISGF3 vs. GAF 34 
 19 
As outlined above, the biological phenotype of ∆M27-MCMV and the results of our 1 
molecular analysis of the JAK-STAT signalling events in MCMV-infected cells indicate that 2 
ISGF3 complexes are rather resistant against the herein described cytomegaloviral inhibitor, 3 
whereas STAT1 and STAT3 homodimers are sensitive. Such a differential inhibition can only 4 
be explained if we infer that the (co-) transcription factor complexes (e.g. p300, CBP, the 5 
mediator complex and others) recruited by ISGF3 significantly differ from the complexes 6 
utilized by STAT1 and/or STAT3 homodimers. 7 
STAT1 is absolutely essential for the generation of functional ISGF3 complexes and thus type 8 
I IFNs fail to induce gene expression in STAT1-deficient cells. Nevertheless, a full length 9 
transactivation domain (TAD) of STAT1 seems not to be required for ISGF3 signalling: The 10 
short splice isoform of STAT1 (STAT1β) lacks large parts of the C-terminal STAT1 TAD 11 
and is insufficient to generate transcriptionally active STAT1 homodimers. However, 12 
functional ISGF3 complexes can be formed by this STAT1β splice isoform (61). Thus, the 13 
transcriptional activation of ISGF3 relies on the TAD of STAT2 whereas the transcriptional 14 
activation of STAT1 homodimers depends on the TAD of STAT1. Consistently, specific co-15 
regulatory proteins have been described. For example, N-myc and STAT interactor (Nmi) 16 
potentiates STAT-dependent gene expression. Interestingly, Nmi binds all STATs except 17 
STAT2 (62). Additionally, ISGF3 signalling has been shown to require an interaction with the 18 
mediator complex. In this context, STAT2 physically interacts with the mediator components 19 
DRIP77 and DRIP150, but none of the tested mediator complex components co-precipitates 20 
with STAT1 or STAT3 (57). 21 
We infer that the suspected cytomegaloviral inhibitor of JAK-STAT signalling targets a 22 
specific (co-) transactivator involved in STAT1 and STAT3 signalling, which is dispensable 23 
(or redundant) in terms of ISGF3 signal transduction. 24 
 25 
Potential biological implications for the viral inhibition of STAT3 signalling 26 
Given the wealth of knowledge concerning IFN-induced effector mechanisms directly or 27 
indirectly interfering with viral replication, the existence of viral antagonists targeting STAT1 28 
can easily be understood (54). Less obvious is the ‘rationale’ behind the herewith described 29 
viral modulation of STAT3 signal transduction, especially because several viruses (e.g. Rous 30 
Sarcoma Virus, Hepatitis C Virus, Herpesvirus Saimiri, Epstein-Barr Virus and Kaposi’s 31 
Sarcoma-associated Herpesvirus) encode proteins which induce genuine STAT3 activation 32 
(63-67). Nevertheless, other viruses besides MCMV also inactivate STAT3, e.g. mumps virus 33 
induces proteasomal degradation of STAT3 (68). This divergence might be based on 34 
 20 
differences in the viral life styles and authentic STAT3 activation may be correlated with cell 1 
transforming potential. 2 
A simple explanation for STAT3 inactivation would be that MCMV targets STAT1 and that 3 
STAT3 inhibition represents merely a ‘collateral damage’ resulting from overlapping 4 
transcriptional co-activators used by both STATs. We favour the interpretation that STAT3 5 
modulation constitutes a selective advantage for MCMV on its own. Recently, it was shown 6 
that IL-6 induces PML expression via STAT3 (69). PML is well known to restrict herpesvirus 7 
replication (70) which drove HCMV to evolve specific antagonists (71). Therefore, one 8 
explanation for the blockade of STAT3 signal transduction might be interference with the 9 
induction of antiviral proteins like PML. 10 
But why should MCMV retain STAT3 phosphorylation? MCMV infection leads to 11 
dramatically increased IL-6 secretion (72) and it has been shown that in absence of STAT3, 12 
IL-6 induces STAT1 activation and initiates IFNγ-like responses (73). Thus, it is tempting to 13 
speculate that MCMV invented this elaborated interference with STAT3 signalling (instead of 14 
e.g. STAT3 degradation) to avoid that IL-6 in turn induces an IFNγ-like antiviral program. 15 
Even though phosphorylated STAT3 is transcriptionally inert in terms of canonical STAT3 16 
signal transduction and fails to induce classic target genes (e.g. SOCS3), it might nevertheless 17 
fulfil other pro-viral functions in MCMV-infected cells. In this respect, it is noteworthy that 18 
the HCMV-encoded IE1-pp72 utilizes phosphorylated STAT1 to elicit an IFN-like host cell 19 
response (51) and that the HCMV major IE promoter (MIEP) contains IFN-responsive 20 
promoter elements (called VRS1) which resemble STAT-binding sites (or GAS elements) 21 
(74). It remains to be elucidated whether phosphorylated STAT3 binds to the MCMV genome 22 
to modulate viral gene expression. 23 
 24 
Implications for the interpretation of CMV-induced and CMV-expressed cytokines 25 
CMVs induce cellular interleukins like IL-6 and IL-10 whereas HCMV even encodes 26 
different splice isoforms of a viral IL-10 homolog. IL-6 and IL-10 signal via STAT3, 27 
therefore an inhibition of STAT3-dependent signal transduction has considerable implications 28 
for the interpretation of viral cytokine induction. Our results show that cells (e.g. fibroblasts) 29 
which are productively infected by MCMV do not respond with a canonical STAT1/3 30 
signalling. Therefore, secretion of STAT3-activating cytokines induced by CMV either have 31 
to bypass the described inhibition or the cytokines exclusively act in a paracrine manner to 32 
manipulate uninfected bystander cells. This interpretation is consistent with findings showing 33 
that conditioned media derived from MCMV-infected cells induced MHC class II down 34 
 21 
regulation upon transfer to uninfected cells in an IL-10-dependent manner (14). Additionally, 1 
the expression of the viral STAT3 antagonists will most likely occur delayed in less 2 
permissive cells (e.g. macrophages) so that STAT3-dependent signalling of cytokines like IL-3 
10 is preserved longer to execute the observed autocrine MHC II down modulation. 4 
 5 
An additional MCMV-encoded IFN antagonist 6 
Besides the implications for the understanding of phosphorylated STAT molecules and their 7 
feedback regulation, our data reveal the existence of a yet unknown IFN antagonist encoded 8 
by MCMV in addition to pM27. This inhibitor targets STAT1/3-dependent gene expression 9 
on the transcriptional level without disturbing STAT1/3 phosphorylation. Our future work 10 
will be focused on the elucidation of the identity of this particular viral inhibitor. 11 
Since STAT1 and STAT3 fail to execute their transcriptional program despite their tyrosine 12 
phosphorylation, the identity of the cellular interaction partner(s) of such an inhibitor might 13 
be relevant for an understanding of STAT-induced transcription. 14 
Taken together, our findings reveal the existence of a novel MCMV-encoded inhibitor of 15 
JAK-STAT signalling which acts downstream of effected phosphorylation, but precludes 16 
respective gene expression. This inhibition has the paradoxical consequence that 17 
phosphorylation (normally a hallmark of activation) of STAT1 is prolonged and STAT3 18 
phosphorylation is even ‘autonomously’ induced, due to blockade of the negative feedback 19 
regulation. 20 
 21 
22 
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Figure legends: 1 
Fig. 1: MCMV abrogates STAT1 signalling after effected STAT1 Y701 phosphorylation, 2 
nuclear localization and DNA-binding 3 
(A) Cells were infected with MCMV or left uninfected. 1 d post infection (d p. i.) cells were 4 
incubated for 30 min with mouse IFNγ (500 U/ml) and fractionated protein lysates (cytoplasm 5 
versus nucleoplasm) were prepared, normalized and subjected to SDS polyacrylamid gel 6 
electrophoresis (PAGE). The gel was blotted and the indicated proteins were detected by 7 
immunoblotting with indicated antibodies. (B) Nuclear translocation of STAT1 was tested as 8 
described in the M&M section (C) Native protein lysates of uninfected, wt-MCMV- or 9 
∆M27-infected cells treated with IFNα, IFNγ or left untreated were subjected to EMSA 10 
analysis using a GAS probe as described in the M&M section. The identity of STAT1-11 
containing complexes (indicated as ‘GAF’) was ensured by a super-shift upon addition of a 12 
STAT1-specific antibody to a lysate of IFNγ-conditioned cells (compare lanes 1 and 4). (D) 13 
Cells were either mock- or MCMV-infected (for 24 h with 10 PFU/cell) and subsequently 14 
exposed to 100 U/ml IFNγ for 30 min. Cells were lysed and subjected to ChIP analysis as 15 
described in the M&M section. (E) A clonal NIH3T3-based cell line harbouring a luciferase 16 
reporter gene under the control of a GAS promoter/enhancer element was generated. Cells 17 
were infected (10 PFU/cell) with the indicated viruses for 24 h and then IFN stimulated (100 18 
U/ml) for 5 h. Afterwards, luciferase activity was quantified as described in the M&M 19 
section. Arithmetic mean and standard deviation are depicted. Statistical significance was 20 
tested using t-test (unpaired, two-sided) compared to the respective mock samples. (F) IFNγ-21 
dependent (500 U/ml; 2 h) induction of IRF-1 mRNA in uninfected and MCMV-infected 22 
(4+2 h p. i.; 10 PFU/ml) cells was tested by northern blotting. 23 
 24 
Fig. 2: MCMV gene expression is required to induce IFNAR1-independent STAT3 25 
phosphorylation 26 
(A) Lysates of M2-10B4 cells infected with wt-MCMV (24 h p. i.; 10 PFU/cell) or left 27 
uninfected were subjected to immunoblot analysis detecting the indicated proteins. For a 28 
comparison, cells were incubated for 30 min with 20 ng/ml Hyper-IL-6. (B) As in (A) but 29 
M2-10B4 cells were compared with STAT3-deficient cells. (C) mHTC-K2 were infected with 30 
wt-MCMV or left uninfected. Protein lysates were analyzed by immunoblotting. In contras to 31 
previous experiments, separate membranes were probed individually with the indicated 32 
antibodies and not sequentially using the same membrane. (D) NIH3T3 cells were infected 33 
with MCMV (10 PFU/cell). At indicated time points post infection, cells were lysed and 34 
 30 
analysed by immuno blotting using STAT3- (left panel) and phospho-STAT3-specific 1 
antibodies (right panel). Four independent lysates were quantified. Shown is the relative 2 
abundance compared to mock cells. The mean values are depicted as dotted line. (E) As 3 
indicated, NIH3T3 cells were infected with grading infectious doses of wt-MCMV and 4 
analyzed by immunoblotting. (F) NIH3T3 and IFNAR1-deficient cells were stimulated for 30 5 
min with 500 U/ml IFNα and STAT3 phosphorylation was tested by immunoblotting. (G) To 6 
describe the time course of viral STAT3 modulation, uninfected and wt-MCMV infected (10 7 
PFU/cell) cells (IFNAR1-deficient and identically immortalized C57BL/6 fibroblasts) were 8 
lysed at indicated times [h] p. i. and probed for phospho-Y705-STAT3 and overall STAT3 9 
amounts. (H) The necessity of viral gene expression for STAT3 modulation was tested by 10 
irradiating MCMV with grading UV doses (in J/m2) prior to ‘infection’. 24 h p. i. cells were 11 
lysed and subjected to immunoblotting. (I) The dispensability of cytomegaloviral late gene 12 
expression was analyzed by ganciclovir (GCV) treatment which inhibits genome replication 13 
and thereby largely reduces accompanying late gene expression. 14 
 15 
Fig. 3: The MCMV-induced STAT3 phosphorylation is restricted to infected cells and 16 
not influenced by IL-6, IL-10 or JAK2 17 
(A) NIH3T3, IL-6-, IL-10- and JAK2-deficient cells were tested for their capacity to support 18 
the MCMV-induced STAT3 modulation. Cells were infected (10 PFU/cell, 24 h p. i.) and 19 
subjected to immunoblotting using indicated antibodies. (B) In a medium transfer experiment, 20 
conditioned media of MCMV infected cells (which exhibit pronounced STAT3 Y705 21 
phosphorylation) was inactivated (either by sterile filtration [‘sterile’] or by UV irradiation 22 
[‘UV’]) and subsequently transferred to uninfected NIH3T3 or RAW cells. STAT3 23 
phosphorylation was assessed by immunoblotting. (C) In a transwell experiment (0.4 µm 24 
membrane pore size), MCMV-infected and mock-infected cells were co-incubated sharing the 25 
same media. Cells were lysed separately and analyzed by immunoblotting. (D) wt-MCMV 26 
infected cells (10 PFU/ml; 24 h p. i.) and uninfected cells were cultured during the infection 27 
cycle with grading concentrations of foetal bovine serum (0 – 20% [v/v]). Cells were lysed 28 
and assessed by immunoblotting using the indicated antibodies. MCMV infection was 29 
visualized using a polyclonal anti-MCMV mouse immune serum (‘α-MCMV’). One virus-30 
specific band is depicted. Please note, that the viral gene expression was to a certain extend 31 
increased in cells being treated with higher FCS concentrations (data not shown). 32 
 33 
Fig. 4: MCMV interferes with STAT3-dependent gene expression 34 
 31 
(A) Fractionated protein lysates (cytoplasmic versus nucleoplasmic) of uninfected or wt-1 
MCMV infected cells (10 PFU/ml, 24 h p. i.) treated for 1 h with or without 20 ng/ml Hyper-2 
IL-6 were subjected to immunoblot analysis using the indicated antibodies. STAT3 target 3 
gene expression was analyzed by assessing SOCS3 amounts. (B) Northern blot analysis 4 
reveals the inhibition of Hyper-IL-6- (1 h; 20 ng/ml) and/or IFNγ (1 h; 500U/ml) -dependent 5 
mRNA induction of SOCS3, SOCS1, IRF-1, JunB, cEBPDδ, STAT3 and c-Myc in cell 6 
infected with wt-MCMV (24+1 h p. i.). Appropriate RNA loading of the blotted gel was 7 
ensured by ethidium bromide staining of ribosomal 18S and 28S RNAs (‘rRNA’) and MCMV 8 
infection was documented by using an ie1-specific DNA-probe for hybridization. 9 
 10 
Fig. 5: MCMV infection impairs Ser 727 phosphorylation of STAT3 11 
NIH3T3 cells were infected with 10 PFU/cell wt-MCMV, ∆M27-MCMV, UV-irradiated 12 
(10,000 J/m2) wt-MCMV or left uninfected. 24 h p. i. cells were either treated with 20 ng/ml 13 
Hyper-IL-6, 500 U/ml IFNγ or left untreated for 15 min. Cells were lysed and subjected to 14 
immunoblot using the indicated antibodies. 15 
 16 
Fig. 6: MCMV infection prolongs STAT1 phosphorylation 17 
NIH3T3 cells were infected with wt-MCMV or ∆M27-MCMV or left uninfected (24 h p. i.; 5 18 
PFU/ml) and subsequently pulsed with IFNγ (500 U/ml; 30 min). Afterwards, IFNγ was 19 
removed by vigorously washing the cells and protein lysates were prepared at the indicated 20 
time points post washing procedure (‘chase’ time in min) to follow the kinetic of STAT1 21 
phosphorylation and dephosphorylation. The indicated proteins were detected by 22 
immunoblotting. 23 
 24 
Fig. 7: Neither pIE1 nor pM27 are essential for the cytomegaloviral STAT3 regulation. 25 
(A) NIH3T3 cells were infected (10 PFU/ml; 24 h p. i.) with an IE1-deletion MCMV, the 26 
respective parental virus (‘wt’) or left uninfected. Cells treated by Hyper-IL-6 (1 h; 20 ng/ml) 27 
or left untreated. Mixtures of nuclear and cytoplasmatic fractions (1/1 ratio) were subjected to 28 
immunoblot analysis. The deficiency for IE1 was documented by probing pIE1-pp89 and 29 
comparable infection was ensured by probing the viral protein pM45. (B) As in (A), but wt-30 
MCMV and ∆M27-MCMV were compared. 31 
 32 
Fig. 8: MCMV reveals a dynamic equilibrium of STAT3 activation and inactivation. 33 
 32 
(A) The supposed dynamic equilibrium of STAT3 phosphorylation, expression of mediators 1 
of the negative feed-back loop (e.g. SCOS3) and STAT3 dephosphorylation in MCMV 2 
permissive cells (NIH3T3) was tested by incubation of cells with the broad spectrum 3 
phosphatase inhibitor sodium vanadate (Na3VO4; 100 µM) for the indicated time periods. 4 
Cells were lysed and subjected to immunblot analysis. (B) as in (A) but MCMV-infected and 5 
uninfected cells were treated with 10 and 100 µM sodium vanadate, respectively, starting at 6 
the time of infection or one day post infection. 7 








